Why So Few Drugs for Alzheimer’s Disease? Are Methods Failing Drugs?

Title:Why So Few Drugs for Alzheimer’s Disease? Are Methods Failing Drugs?

Volume: 7 Issue: 7

Author(s): R. E. Becker and N. H. Greig

Affiliation:

Keywords: Alzheimer's disease, Alzheimer clinical trial, error management, checklist, tarenflurabil, metrifonate, phenserine.

Abstract: Recent studies of Alzheimer’s disease (AD) and other neuropsychiatric drug developments raise questions whether failures of some drugs occur due to flaws in methods. In three case studies of recent AD drug development failures with phenserine, metrifonate, and tarenflurbil we identified methodological lapses able to account for the failures. Errors in complex systems such as drug developments are both almost inescapable due to human mistakes and most frequently hidden at the time of occurrence and thereafter. We propose preemptive error management as a preventive strategy to exclude or control error intrusions into neuropsychiatric drug developments. We illustrate the functions we anticipate for a preemptive error management preventive strategy with a checklist and identify the limitations of this aspect of the proposal with three drug examples. This strategy applies core scientific practices to insure the quality of data within the current context of AD drug development practices.

Cite this article as:

E. Becker R. and H. Greig N., Why So Few Drugs for Alzheimer’s Disease? Are Methods Failing Drugs?, Current Alzheimer Research 2010; 7 (7) . https://dx.doi.org/10.2174/156720510793499075